Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
2011

Free IGF-1 Predicts Sensitivity to Figitumumab in NSCLC Patients

Sample size: 110 publication Evidence: moderate

Author Information

Author(s): Gualberto A, Hixon M L, Karp D D, Li D, Green S, Dolled-Filhart M, Paz-Ares L G, Novello S, Blakely J, Langer C J, Pollak M N

Primary Institution: The Department of Clinical Development and Medical Affairs, Pfizer Oncology

Hypothesis

Pre-treatment levels of circulating free IGF-1 can predict which NSCLC patients will benefit from figitumumab treatment.

Conclusion

Free IGF-1 may help identify NSCLC patients who benefit from figitumumab therapy.

Supporting Evidence

  • Patients with higher free IGF-1 levels had better progression-free survival on figitumumab.
  • Free IGF-1 levels correlated with tumor vimentin expression and inversely with E-cadherin.
  • High pre-treatment levels of free IGF-1 were predictive of clinical benefit from figitumumab.

Takeaway

Doctors can use a blood test to see if a medicine called figitumumab will help some lung cancer patients.

Methodology

The study tested pre-treatment circulating levels of free IGF-1 in 110 advanced NSCLC patients enrolled in a phase II trial.

Limitations

The study was exploratory and not sufficiently powered for subset safety analysis.

Participant Demographics

68% men, median age 64 years, 49% adenocarcinoma histology, 80% stage IV.

Statistical Information

P-Value

0.005

Confidence Interval

0.22–1.38

Statistical Significance

p=0.005

Digital Object Identifier (DOI)

10.1038/sj.bjc.6605972

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication